leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 09:58:15 - browse：5414

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Ohio still needs to do more to protect the right to abortion

WSS

NIH chief: government has fallen behind pharma on clinical trials

Google and Epic fight stronger regulation of AI in health care

Group opposing PBM reform sets lobbying record

Publishing genetic code of viruses could cause disaster

What is STAT's opinion section for?

WHO calls for emergency meeting on new China virus, as cases spread

focus

leisure time

Gilead needs Arcellx more than ever

focus

Peter Hotez and the public health issue of online harassment

FDA approves RSV monoclonal antibody for infants, toddlers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Wegovy in the brain & pivotal Alzheimer's data

Hepatitis C has a cure — but many Americans still lack access to it

Medical school prerequisites are outdated

Sports medicine is finally prioritizing gender equality

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

New air purifier tech could be key to improving indoor air quality

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

focus

Cancer diagnosis changes perspective doctor, former hospital CEO

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Experimental asthma app from Apple and Anthem shows promise

Experimental asthma app from Apple and Anthem shows promise

NIH chief: government has fallen behind pharma on clinical trials

Healthy food access boosts outcomes in two studies

knowledge

entertainment

hotspot

focus